Page 3 - Solid Tumor News Today

Understanding the role of an essential protein inside regulatory T cells could be critical in reverse-engineering a treatment for solid tumors.

Research on regulatory T cells is building towards a durable and long-lasting treatment for many solid cancers.

Median overall survival for GPS and Keytruda® combination was 18.4 Months compared to 13.8 Months in a Keytruda® single agent study (KEYNOTE-028) and 11-14...

BPRDPO-56 is under clinical development by Molecular Targeting Technologies and currently in Phase I for Solid Tumor.

NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel

Faculty position, Department of Oncology – Solid Tumor Division job in Memphis, Tennessee with St. Jude Children's Research Hospital (St. Jude). Apply Today.

WASHINGTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- As per Vantage Market Research, the Global Immuno-Oncology Clinical Trials Market has been steadily growing over the years due to increasing incidence of cancer, advancements in cancer research, the growing demand for personalized medicine, increased research and development activities in the field of immuno-oncology, as well as advancements in technology and supportive regulatory frameworks. According to Vantage Market Research, the global Immuno-O

PHILADELPHIA, Aug. 24, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. , a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced...

Faculty position – Department of Oncology, Division Director of Leukemia-Lymphoma Division job in Memphis, Tennessee with St. Jude Children's Research Hospital (St. Jude). Apply Today.

Studying a way to improve treatment of solid tumors..